EUVIMEDEUVIMED entdecken
CrossrefInfokarte

New Paradigms in Hepatitis D: Screening, Treatment, and the Path to Cure

Toni Herta, Christian Gaebler, Johannes Wiegand, Münevver Demir, Frank Tacke

Seminars in Liver Disease · 2026-11-06

DOI: 10.1055/a-2990-0086 ↗
AbstractBibliografische Angaben

Abstract

Chronic hepatitis D virus infection, also known as chronic hepatitis delta, remains the most severe form of chronic viral hepatitis, associated with accelerated liver disease progression, cirrhosis, decompensation, and hepatocellular carcinoma. Recent years have seen major advances in screening strategies and antiviral therapies for hepatitis D. This review discusses evidence supporting broader hepatitis D screening among hepatitis B surface antigen (HBsAg)-positive individuals and practical considerations for implementation across epidemiological settings, and reviews current and emerging treatments—entry inhibition (bulevirtide), prenylation inhibition (lonafarnib), immune-modulatory therapies (pegylated interferons), and HBsAg-targeting approaches (tobevibart, elebsiran, brelovitug, and nucleic acid polymers)—focusing on treatment response and durability of viral suppression. In conclusion, emerging therapies have substantially improved antiviral efficacy, shifting the focus of hepatitis D management from on-treatment suppression toward durable off-treatment control and functional cure, changing the diagnosis, treatment, and long-term management of chronic hepatitis D.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →